Key terms
About ENVB
Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ENVB news
Mar 21
10:52am ET
Here’s What You Missed in Cannabis, Psychedelics This Week
Mar 19
7:12am ET
Enveric Biosciences Explores Joint Disease Treatment Licensing
Mar 19
7:10am ET
Enveric in out-licensing deal for chemical entities to treat joint diseases
Mar 12
7:25am ET
USPTO issues patent to Enveric titled ‘Multi-Substituent Psilocybin Derivatives’
Mar 11
12:43pm ET
Enveric Biosciences to sell 228,690 shares at $1.41 in direct offering
Feb 29
11:29am ET
Here’s What You Missed in Cannabis, Psychedelics This Week
Feb 29
11:29am ET
Here’s What You Missed in Cannabis, Psychedelics This Week
Feb 29
7:38am ET
Enveric in compound out-licensing deal with biotech firm with
Feb 29
7:14am ET
Enveric Biosciences Plans to Out-License Compound Classes
Feb 23
8:10am ET
Enveric Biosciences to sell cancer-related patent portfolio, terms undisclosed
Feb 22
11:19am ET
Here’s What You Missed in Cannabis, Psychedelics This Week
Feb 22
11:19am ET
Here’s What You Missed in Cannabis, Psychedelics This Week
Feb 21
8:23am ET
Enveric Biosciences Unveils New Mental Health Compounds
Feb 10
4:07am ET
Enveric Biosciences Granted Extension to Avoid Nasdaq Delisting
Jan 30
6:03am ET
Enveric Biosciences initiated with a Buy at H.C. Wainwright
Jan 11
4:45pm ET
Enveric Biosciences files to sell 2.24M shares of common stock for holders
Dec 29
8:57am ET
Enveric Biosciences sells 1.122M shares at $1.37 in private placement
Dec 28
8:04am ET
Enveric Biosciences selects EB-003 as lead in ‘next gen’ EVM301 series
Dec 27
8:09am ET
Enveric Biosciences reports progress on developing lead prodrug candidate EB-373
No recent news articles are available for ENVB
No recent press releases are available for ENVB
ENVB Financials
Key terms
Ad Feedback
ENVB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ENVB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range